We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, AbbVie (ABBV - Free Report) closed at $216.75, marking a -2.32% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.26%. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq increased by 0.25%.
Coming into today, shares of the drugmaker had lost 1.08% in the past month. In that same time, the Medical sector gained 0.92%, while the S&P 500 gained 1.57%.
Investors will be eagerly watching for the performance of AbbVie in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 4, 2026. The company is expected to report EPS of $3.28, up 51.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $16.37 billion, up 8.38% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $10.57 per share and revenue of $60.93 billion. These results would represent year-over-year changes of +4.45% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. AbbVie presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, AbbVie is holding a Forward P/E ratio of 15.38. This signifies no noticeable deviation in comparison to the average Forward P/E of 15.38 for its industry.
We can also see that ABBV currently has a PEG ratio of 0.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 216, positioning it in the bottom 12% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
In the latest trading session, AbbVie (ABBV - Free Report) closed at $216.75, marking a -2.32% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.26%. On the other hand, the Dow registered a gain of 0.6%, and the technology-centric Nasdaq increased by 0.25%.
Coming into today, shares of the drugmaker had lost 1.08% in the past month. In that same time, the Medical sector gained 0.92%, while the S&P 500 gained 1.57%.
Investors will be eagerly watching for the performance of AbbVie in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 4, 2026. The company is expected to report EPS of $3.28, up 51.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $16.37 billion, up 8.38% from the prior-year quarter.
ABBV's full-year Zacks Consensus Estimates are calling for earnings of $10.57 per share and revenue of $60.93 billion. These results would represent year-over-year changes of +4.45% and 0%, respectively.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.09% upward. AbbVie presently features a Zacks Rank of #3 (Hold).
Looking at its valuation, AbbVie is holding a Forward P/E ratio of 15.38. This signifies no noticeable deviation in comparison to the average Forward P/E of 15.38 for its industry.
We can also see that ABBV currently has a PEG ratio of 0.91. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.61.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 216, positioning it in the bottom 12% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.